<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>29395386</identifier>
<setSpec>1699-7980</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Riera, L</dc:author>
<dc:author>Cocera, R</dc:author>
<dc:author>Narváez, A</dc:author>
<dc:author>Castells-Esteve, M</dc:author>
<dc:author>Suarez, J</dc:author>
<dc:author>Vigués, F</dc:author>
<dc:description xml:lang="en">INTRODUCTION AND OBJECTIVES The management of Prostate cancer (PCa) in renal transplant recipients (RTR) is challenging and remain controversial. Currently there is no consensus about this condition. The aim of the study was to analyse our experience in the diagnosis and management of PCa in RTR. METHOD Retrospective monocentric study of a prospective and consecutive database from 2003-2017. Inclusion of RTR diagnosed of PCa. Staging and treatment in agreement with the contemporary guidelines. The main outcome measures included clinical staging, type of treatment, oncological outcomes and follow-up. RESULTS 1,330 renal transplants were performed (787 males), diagnosed of PCa in 33 RTR (4.2%), mean age 66years±6.3 (51-78). Median PSA was 8.8ng/ml and PSA ratio 0.19. Mean time between renal transplantation and PCa diagnosis 130months±90 (2-236). TREATMENTS Radical prostatectomy (RP) (n=22; 66.7%), Radiation therapy (RT) with Androgen deprivation therapy (ADT) (n=7; 21.2%), Active surveillance (n=3; 9.1%), ADT (n=1; 3%). No graft loss neither impaired renal function due to PCa treatment was reported. After RP two patients (9.1%) presented biochemical recurrence treated with RT. Remission of the 100%. Mean follow-up was 61months±37 (6-132). CONCLUSIONS PCa in renal transplant patients can be managed with the same therapeutic options as in the general population. Active surveillance should also be provided in RTR despite being under immunosuppressive therapy.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Cáncer de próstata</dc:subject>
<dc:subject>Active surveillance</dc:subject>
<dc:subject>Renal transplant</dc:subject>
<dc:subject>Radical prostatectomy</dc:subject>
<dc:subject>Trasplante renal</dc:subject>
<dc:subject>Recidiva bioquímica</dc:subject>
<dc:subject>Prostatectomía radical</dc:subject>
<dc:subject>Vigilancia activa</dc:subject>
<dc:subject>Biochemical recurrence</dc:subject>
<dc:subject>Prostate cancer</dc:subject>
<dc:date>2018 Jan 26 </dc:date>
<dc:title xml:lang="es">Nuestra experiencia en el manejo del cáncer de próstata en pacientes trasplantados renales.</dc:title>
<dc:title xml:lang="en">Our experience in the management of prostate cancer in renal transplant recipients.</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
